Platelet function testing in patients with coronary artery disease: Is the who and the when any clearer than the what and the what then?

Circulation

Volumn 125, Issue 25, 2012, Pages 3073-3075

  Rade, Jeffrey J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

aspirin; clopidogrel; coronary artery disease; Editorials; platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL; CYCLOOXYGENASE 1; THROMBOXANE A2; VON WILLEBRAND FACTOR;

CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDITORIAL; FUNCTION TEST; HIGH ON TREATMENT PLATELET REACTIVITY; HUMAN; LABORATORY DEVICE; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION TEST;

DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; MALE; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS;

EID: 84863184698     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.112094     Document Type: Editorial

References (20)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 2002;324:71-86.
2. CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndroms without ST-segment elevation. N Engl J Med. 2001;345:494-502.
3. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanism, and clinical significance. Thromb Haemost. 2002;88:711-715. (Pubitemid 35345324)
4. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919-933.
5. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1822-1834. (Pubitemid 350007957)
6. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, Moy TF, Becker LC, Faraday N. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA. 2006;295:1420-1427.
7. Gluckman TJ, McLean RC, Schulman SP, Kickler TS, Shapiro EP, Conte JV, McNicholas KW, Segal JB, Rade JJ. Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. J Am Coll Cardiol. 2011;57:1069-1077.
8. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J. 2007;153:175-181. (Pubitemid 46096871)
9. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med. 2007;167:1593-1599. (Pubitemid 47280339)
10. Nazarian SM, Thompson JB, Gluckman TJ, Laws K, Jani JT, Kickler TS, Rade JJ. Clinical and laboratory factors associated with shear-dependent platelet hyper-reactivity in patients on chronic aspirin therapy. Thromb Res. 2009;126:379-383.
11. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007;154:221-231. (Pubitemid 47069129)
12. Bouman HJ, Parlak E, Van Werkum JW, Breet NJ, Ten CH, Hackeng CM, Ten Berg JM, Taubert D. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost. 2010;8:482-488.
13. Breet NJ, Van Werkum JW, Bouman HJ, Kelder JC, Harmsze AM, Hackeng CM, Ten Berg JM. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart. 2011;97: 983-990.
14. Frelinger AL III, Michelson AD, Wiviott SD, Trenk D, Neumann FJ, Miller DL, Jakubowski JA, Costigan TM, McCabe CH, Antman EM, Braunwald E. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel: results from PRINCIPLE-TIMI 44. Thromb Haemost. 2011;106:219-226.
15. Aradi D, Komocsi A, Vorobcsuk A, Rideg O, Tokes-Fuzesi M, Magyarlaki T, Horvath IG, Serebruany VL. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J. 2010;160: 543-551.
16. Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a timedependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation. 2011;124:1132-1137.
17. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-2913. (Pubitemid 36736631)
18. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305:1097-1105.
19. Reny J-L, Berdague P, Poncet A, Barazar I, Nolli S, Fabbro-Peray P, Schved J-F, Bounameaux H, Mach F, de Moerloose P, Fontana P. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation. 2012;125:3201-3210.
20. Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H. High on-aspirin platelet reactivity and clinical outcome in patients with stable coronary artery disease: results from ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J Am Heart Assoc. 2012;1:e000703 doi: 10.1161/JAHA. 112.000703.